GlassScriptPhysician profile
Elizabeth A Wilder
NPI 1649603135
$1,316.58
in general payments reported to CMS, 2019-2025
13 companies · $26.50 in 2025
The $26.50 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $59.63 · 2022: $349 · 2023: $882 · 2025: $26.50.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $908.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $908.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $302.65 | 2021-2023 | Rexulti |
| Novo Nordisk INC | $267.35 | 2021-2023 | Wegovy, Rybelsus, Ozempic |
| Abbvie INC. | $209.03 | 2021-2023 | |
| Lundbeck LLC | $115.52 | 2022-2023 | Rexulti |
| Astrazeneca Pharmaceuticals LP | $110.88 | 2022-2023 | Breztri, Farxiga, Airsupra |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $78.08 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $65.64 | 2022-2023 | Jardiance |
| Radius Health, INC. | $62.40 | 2023-2025 | Tymlos |
| Xeris Pharmaceuticals, INC. | $40.84 | 2022-2023 | Gvoke Hypopen |
| Amgen INC. | $19.37 | 2023 | Evenity, Prolia |
| Novartis Pharmaceuticals Corporation | $15.15 | 2023 | |
| Janssen Pharmaceuticals, INC | $15.03 | 2023 | Xarelto |
| Astellas Pharma US INC | $14.64 | 2023 | Myrbetriq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elizabeth Wilder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.